Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

More Evidence Arthritis/Pain Relieving Drugs May Contribute to Stroke Death

06.11.2014

Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. Stroke is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

The drugs examined in the study, called COX-2 inhibitors, include older drugs diclofenac, etodolac, nabumeton and meloxicam, as well as newer drugs called coxibs, including celecoxib and rofecoxib. COX-2 inhibitors are selective nonsteroidal anti-inflammatory drugs (NSAIDs). The study also looked at non-selective NSAIDs, which include common pain relievers such as ibuprofen and naproxen.

“While newer versions of these COX-2 inhibitors drugs have been pulled off shelves, older ones are still frequently prescribed,” said study author Morten Schmidt, MD, of Aarhus University Hospital in Aarhus, Denmark. “Our study provides further important evidence solidifying the risks of certain arthritic pain relievers and death from stroke.”

For the study, researchers looked at records of 100,243 people hospitalized for a first stroke in Denmark between 2004 and 2012 and deaths within one month after the stroke. Researchers looked at whether participants were current, former, or non-users of these drugs within two months of the stroke.

If they were current users, researchers noted whether people were new users who had just started taking the drug for the first time or were long-term users. They looked at newer generation COX-2 inhibitors, older generation COX-2 inhibitors, and non-selective NSAIDS.

Overall, people who were current users of COX-2 inhibitors were 19 percent more likely to die after stroke than people who did not take the drugs (10.4 percent versus 8.7 percent). New users of the older COX-2 drugs were 42 percent more likely to die from stroke than those who were not taking the drugs. Those taking etodolac were 53 percent more likely to die from stroke.

The researchers found no link between the non-selective NSAIDs and increased stroke death. Also, the study found no link between chronic use of any of the drugs and stroke mortality.

A total of 10,835 of the participants, or 11 percent, were NSAID users; 8,402, or eight percent, were former users; and 80,806, or 81 percent, were non-users. Of the current NSAID users 51 percent used ibuprofen, 27 percent used diclofenac, 11 percent used etodolac, three percent naproxen, one percent celecoxib and 0.5 percent rofecoxib.

“Our study supports stepping up efforts to make sure people with a higher risk of stroke are not prescribed these medications when other options are available,” said Schmidt.

To learn more about stroke, please visit www.aan.com/patients 

The American Academy of Neurology, an association of more than 28,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com

Rachel L. Seroka | American Academy of Neurology

More articles from Studies and Analyses:

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

nachricht Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>